Anemia  >>  HQK 1001  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HQK 1001 / Viracta Therap
NCT01322269: A Study of HQK-1001 in Patients With Sickle Cell Disease

Completed
2
52
US, Canada, RoW
HQK-1001
HemaQuest Pharmaceuticals Inc.
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
03/12
 
NCT01601340: Effects of HQK-1001 in Patients With Sickle Cell Disease

Terminated
2
77
US, Canada, RoW
HQK-1001, Placebo
HemaQuest Pharmaceuticals Inc.
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
11/13
12/13

Download Options